For those switching from Zepbound, the average regain was 5.0 kg
Retatrutide remains investigational, so claims promising a specific first-month percentage go beyond the available peer-reviewed evidence
If and when you switch, you would be removing the GIP mechanism, which plays a meaningful role in Mounjaros stronger average outcomes
The rate of osteoporosis, a disease where the bones become fragile and brittle, was 3.2% in the group not taking the drug, compared to 4.1% in the GLP-1-taking group
And in others, not very much of an effect," Alexander said
States With Limited Type 2 Diabetes GLP-1 Coverage: A smaller subset of the states mentioned above with no coverage for obesity-indicated GLP-1sincluding the District of Columbia, Florida, and New Jerseyalso limits coverage for Type 2 diabetes-indicated GLP-1s